Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aphios has received Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for developing a novel alzheimer's disease Nanodrug.
Subscribe to our email newsletter
Aphios claims that it manufactures pharmaceutical-grade APH-0703 following cGMP guidelines utilising patented manufacturing technology.
The grant will be utilised to develop and evaluate conventional and nanotechnology formulations of APH-0703; measure pharmacologic efficacy in the brain and plasma compartments; cGMP manufacturing of the active pharmaceutical ingredient and nanoformulated drug product at the pilot-scale level.
It will also help the company to establish a Drug Master File; design IND-enabling preclinical studies and Phase I/II clinical trials; and draft IND package for the US FDA.